| Tolfenamic acid |
SAS parameters were evaluated for solid state property modification and improvement of dissolution profile of tolfenemic acid. |
SAS technology was efficient in modifying the solid-state. It produced microparticles with improved dissolution behavior. |
[37] |
|
N-acetyl-cysteine |
The study aimed to micronize N-acetylcysteine by the anti-solvent SEDS technique. |
Micronized N-acetylcysteine presented prominent biological activity (100 times) depicted by lower minimum inhibitory concentration compared to non-micronized N-acetylcysteine |
[38] |
| Curcumin |
Curcumin based dye extract was developed employing SAS. Eudragit® L100, Pluronic® 127 and tween 20 were added to improve the aqueous solubility and stability. |
Formulation of a soluble curcumin was carried out for food application. Highest aqueous stability and solubility was observed at pH 4. The mean diameter and zeta potential of the amorphous curcumin particles was 5667.4 nm and 11.21 mV respectively. |
[39] |
| Warfarin |
To determine solubility of warfarin in supercritical CO2 using SAS |
Regular crystals of warfarin with a mean particle size of 6.6 μm were produced |
[40] |
| Irbesartan |
To improve the dissolution of irbesartan through solid dispersions using SAS concept. |
The crystalline state of the drug was transformed into the amorphous state. The dissolution was enhanced after formation of irbesartan solid dispersions |
[41] |
| Azithromycin |
Solid dispersions of azithromycin were developed utilizing variable amounts of PEG 6000, sorbitol, SLS and Poloxamer 188, |
The amorphous solid dispersions of azithromycin demonstrated enhanced solubility with PEG 6000 and SLS. |
[42] |
